El día 16 de Noviembre comienza en Dallas el congreso de la AHA 2013. Tal y como hemos hecho en otras ocasiones, comentaremos en el blog los resultados de los Late-Breaking Clinical Trials.
En concreto, nos centraremos en las sesiones siguientes:
DOMINGO, 17 NOVIEMBRE 2013
LBCT.01.Acute Cardiovascular and Cerebrovascular Care.
Nitrites in Acute Myocardial Infarction: NIAMI – This trial was designed to assess the efficacy of sodium nitrite in reducing myocardial injury in patients with acute ST elevation MI.
Blood Pressure Reduction Among Acute Ischemic Stroke Patients: A Randomized Controlled Clinical Trial: This trial was designed to test the effectiveness of blood pressure reduction on short-term case-fatality and dependency among patients with acute ischemic stroke.
Randomized Clinical Trial of Pre-hospital Induction of Mild Hypothermia in Out-of-Hospital Cardiac Arrest Patients Using a Rapid Infusion of 4oC Normal Saline: The aims of this randomized clinical trial were to determine whether early in-field cooling improves survival, functional status in resuscitated cardiac arrest patients.
Target Temperature Management 33°C Versus 36°C After Out-of-hospital Cardiac Arrest, A Randomized, Parallel Group, Assessor Blinded Clinical Trial: TTM – This randomized trial was designed to investigate the optimal target temperature management strategy after out-of-hospital cardiac arrest with regard to survival, neurological function and safety.
LUNES, 18 NOVIEMBRE 2013
LBCT.02.Prevention: From Schools to Countries.
Promotion of Cardiovascular Health in Preschool Children: 36-month Cohort Follow-up: This study reports the beneficial impact of an educational intervention after 36 months in preschoolers in knowledge and attitudes regarding healthy eating and living an active lifestyle.
Randomized Trial of Social Network Lifestyle Intervention for Obesity: MICROCLINIC Intervention Results and 16-Month Follow-up: This trial was designed to test the effectiveness of a social network lifestyle intervention program for weight loss.
Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures (Medication Study) After Acute Coronary Syndrome Hospital Discharge: The objective of the Medication study was to test a multi-faceted intervention to improve adherence to cardiac medications and secondary prevention measures in the year after ACS hospital discharge.
China Rural Health Initiative – Sodium Reduction Study: the Effects of a Community-Based Sodium Reduction Program on 24hr Urinary Sodium and Blood Pressure in Rural China: China Rural Health Initiative: Sodium Reduction Study: a cluster randomized trial designed to evaluate the effects of a rural community-based sodium reduction program on 24-hour urine sodium excretion and blood pressure.
LBCT.03.Medical and Surgical Approaches to Improving Heart Failure Outcomes.
Atrial Antitachycardia Pacing and Managed Ventricular Pacing Reduce the Endpoint Composed by Death, Cardiovascular Hospitalizations and Permanent Atrial Fibrillation Compared to Conventional Dual Chamber Pacing in Bradycardia Patients: Results of the Minerva Randomized Study: This trial was designed to evaluate the best pacing mode in patients suffering from bradycardia and atrial fibrillation.
Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) Trial: The ROSE AHF trial was designed to determine whether the addition of low dose dopamine (2 ug/kg/min) or low dose nesiritide (0.005 ug/kg/min without bolus) to optimal diuretic dosing will enhance renal function and decongestion in acute heart failure.
Severe Ischemic Mitral Regurgitation: Is it Better to Repair or Replace the Valve?: The CTSN SMR trial was designed to evaluate the safety and effectiveness of mitral valve repair versus replacement in patients with severe ischemic MR.
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT): The specific aim of this trial is to determine if treatment with an aldosterone antagonist (spironolactone) can safely produce a clinically meaningful reduction in the time to cardiovascular mortality, aborted cardiac arrest and heart failure hospitalization, compared with placebo, in adults with preserved cardiac function heart failure.
LBCT.04.Therapeutic Advances in Coronary and Peripheral Vascular Disease.
One Year Mortality in STEMI Patients Randomized to Primary PCI or a Pharmaco-invasive Strategy. The Stream 1 Year Follow-up: The 1 year follow-up of the STREAM trial comparing primary PCI with pharmaco-invasive strategy in STEMI patients unable to undergo primary PCI within one hour of presentation.
Secretory Phospholipase A2 Inhibition with Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome: Results of the VISTA-16 Study: This trial was designed to evaluate whether a sPLA2 inhibitor would reduce cardiovascular events in acute coronary syndrome patients.
Randomized Comparison of Endovascular Revascularization Plus Supervised Exercise Therapy Versus Supervised Exercise Therapy Only in Patients with Peripheral Artery Disease and Intermittent Claudication: Results of the Endovascular Revascularization and Supervised Exercise (ERASE) Trial: Randomized comparison of endovascular revascularization plus supervised exercise versus the standard care of supervised exercise only in patients with
PAD and intermittent claudication: Results from the ERASE Trial.
A Randomized Multicenter Clinical Trial of Renal Artery Stenting in Preventing Cardiovascular and Renal Events: Results of the CORAL Study: This study was designed to evaluate the benefit of renal artery stenting, when compared with medical therapy alone, for patients with atherosclerotic renal artery stenosis.
MARTES ,19 de NOVIEMBRE 2013
LBCT.05.New Strategies for Atrial Fibrillation Patients: Rhythm and Thrombosis.
RADAR-AF Trial. A Randomized Multicenter Comparison of Radiofrequency Catheter Ablation of Drivers versus Circumferential Pulmonary Vein Isolation in Patients with Atrial Fibrillation: This trial was designed to evaluate the efficacy and safety of a new radiofrequency catheter ablation strategy aimed at eliminating sources driving atrial fibrillation.
A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study: EU-PACT Warfarin – The trial was designed to evaluate whether genotype-guided dosing for warfarin is superior to standard dosing protocols.
The Clarification of Optimal Anticoagulation through Genetics (COAG) Trial: This trial will determine the utility of pharmacogenetic-based dosing of warfarin in a large diverse population with atrial fibrillation or flutter.
ENGAGE AF-TIMI 48 Primary Results: The ENGAGE AF-TIMI 48 was a large randomized controlled trial comparing the clinical efficacy and safety of two doses of edoxaban, a novel oral anticoagulant, with warfarin in patients with atrial fibrillation.